SSGJ-707  (Synonyms: PF-08634404)

SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer^[1][2][3].

Human IgG4 (S228P) kappa, Isotype Control

Human

PD-1 & VEGF

SSGJ-707 (PF-08634404) inhibits PD-1-mediated T cell dysfunction and restores the anti-tumor immune activity of T cells in the tumor microenvironment^[4].
SSGJ-707 (PF-08634404) blocks VEGF-A-mediated tumor angiogenesis and reverses the immunosuppressive microenvironment induced by VEGF^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29126  [NCBI] & 7422  [NCBI]

Q9NZQ7 & P15692

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

241.16 kDa

Liquid

Colorless to light yellow

[SSGJ-707]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4

• 
  Flow Cytometry analysis of Hela cells labelling PD-1 (red) with SSGJ-707 (anti-PD-1) (HY-P991628). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control.
• 
  Flow Cytometry analysis of K562 cells labelling VEGF (red) with SSGJ-707 (HY-P991628). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Immobilized Human PD-1 Protein, His tag can bind SSGJ-707. The EC₅₀ for this effect is 43.15 ng/mL.
• 
  Immobilized rhVEGF can bind SSGJ-707. The EC₅₀ for this effect is 74.03 ng/mL.

• [1]. Heiser R A, Zuck M, Sakai C, et al. Characterization and functional evaluation of PF-08634404 (SSGJ-707) a tetravalent PD-1 x VEGF bispecific for the treatment of cancer[J]. Cancer Research, 2026, 86(7_Supplement): 5541-5541.

  [2]. Wu L, Xu H, et al. 1328 SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): Results from a phase 2 study[J]. 2025.

  [3]. Álvarez-Vallina L, et al. Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L) 1 antibodies[J]. Frontiers in Immunology, 2026, 17: 1736806.

  [4]. Leone GM, et al. Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future. Int J Mol Sci. 2025;26(22):11055. Published 2025 Nov 15.  [Content Brief]